MoonLake Immunotherapeutics financial data

Symbol
MLTX on Nasdaq
Location
Zug, Switzerland
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1512% % -63%
Debt-to-equity 23% % 665%
Return On Equity -56% % -260%
Return On Assets -45% % -201%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $1,140,000,000 USD 1.8%
Weighted Average Number of Shares Outstanding, Basic 63,369,984 shares 0.75%
Weighted Average Number of Shares Outstanding, Diluted 63,369,984 shares 0.75%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $187,215,302 USD 133%
General and Administrative Expense $41,982,780 USD 50%
Operating Income (Loss) $229,198,082 USD -111%
Income Tax Expense (Benefit) $404,199 USD 42%
Net Income (Loss) Attributable to Parent $210,498,517 USD -161%
Earnings Per Share, Basic -3 USD/shares -163%
Earnings Per Share, Diluted -3 USD/shares -163%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $350,736,000 USD -6.6%
Assets, Current $411,215,000 USD -20%
Property, Plant and Equipment, Net $622,000 USD 7%
Operating Lease, Right-of-Use Asset $1,911,000 USD -41%
Other Assets, Noncurrent $587,000 USD
Assets $414,335,000 USD -20%
Employee-related Liabilities, Current $4,199,000 USD 44%
Liabilities, Current $48,368,000 USD 141%
Operating Lease, Liability, Noncurrent $486,000 USD -75%
Liabilities $123,144,000 USD 442%
Accumulated Other Comprehensive Income (Loss), Net of Tax $278,000 USD -90%
Retained Earnings (Accumulated Deficit) $400,486,000 USD -111%
Stockholders' Equity Attributable to Parent $288,906,000 USD -41%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $291,191,000 USD -41%
Liabilities and Equity $414,335,000 USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $38,140,000 USD -155%
Net Cash Provided by (Used in) Financing Activities $73,122,000 USD 43%
Net Cash Provided by (Used in) Investing Activities $56,246,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $91,140,000 USD 1153%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $350,736,000 USD -6.6%
Deferred Tax Assets, Valuation Allowance $24,931,857 USD 121%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure 0%
Deferred Tax Assets, Gross $25,001,496 USD 121%
Operating Lease, Liability $1,985,000 USD -41%
Depreciation $22,813 USD 593%
Payments to Acquire Property, Plant, and Equipment $35,000 USD -83%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $213,064,147 USD -162%
Lessee, Operating Lease, Liability, to be Paid $2,064,000 USD -42%
Operating Lease, Liability, Current $1,499,000 USD 3.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two $147,000 USD -88%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,269,000 USD -19%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $79,000 USD -60%
Lessee, Operating Lease, Liability, to be Paid, Year Three $147,000 USD 4.8%
Deferred Tax Assets, Operating Loss Carryforwards $20,372,989 USD 203%
Lessee, Operating Lease, Liability, to be Paid, Year Four $100,000 USD -29%
Operating Lease, Payments $368,000 USD 1.1%
Additional Paid in Capital $689,108,000 USD 2%
Depreciation, Depletion and Amortization $378,000 USD 15%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $11,240,596 USD 62%